Comparison of Intravenous Iron Infusion or Oral Iron for Treatment of Moderate Postpartum Anemia
Öz
Anahtar Kelimeler
Kaynakça
- 1. Milman N (2011) Postpartum anemia I: definition, prevalence, causes and consequences. Ann Hematol 90:1247–1253 2. Milman N. Anemia—still a major health problem in many parts of the world! Ann Hematol 2011; 90:369–377. 3. World Health Organization (1999) Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement. World Health Organization, Geneva 4. Potts M, Campbell M (2004) Three meetings and fewer funerals: misoprostol in postpartum hemorrhage. Lancet 364:1110–1111 5. Tsu VD, Shane B (2004) New and underutilized technologies to reduce maternal mortality: call to action from a Bellagio workshop. Int J Gynecol Obstet 85(Suppl 1):S83–S93 6. Bergmann RL, Richter R, Bergmann KE, Dudenhausen JW (2010) Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol 150:126–131 7. Khalafallah AA, Dennis AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy 2012;2012:630519. doi: 10.1155/2012/630519. Epub 2012 Jun 26. 8. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnostik und Therapie der Anämie in der Schwangerschaft und postpartal. Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe. Expertenbrief 2007 no. 22 9. Beris P, Maniatis A, on behalf of the NATA working group on intravenous iron therapy. Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. Transfusion Alternatives in Transfusion Medicine 2007;9 Suppl 1:29 10. Milman N (2012) Postpartum anemia II: prevention and treatment. Ann Hematol (2012) 91:143–154 11. Venofer®. Summary of Product Characteristics www.medicines. org.uk Accessed February 6th 2011 12. CosmoFer®. Summary of Product Characteristics www.medicines. org.uk Accessed February 6th 2011 13. Ferinject®. Summary of Product Characteristics www.medicines. org.uk Accessed February 6th 2011 14. Lyseng-Williamson KA, Keating GM(2009) Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs 69:739–756 15. Monofer®. Summary of Product Characteristics www.medicines. org.uk Accessed February 6th 2011 16. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. A randomised controlled trial. Obstet Gynecol 110:267–278 17. Seid MH, Derman RJ, Baker JB, BanachW, Goldberg C, Rogers R (2008) Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obst Gynecol 199:435e1–435e7 18. al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T et al (1996) Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 69:121–124 19. al-Ragip A, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A (2005) Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 106:1335–1340 20. Hallak M, Sharon A, Duikman R, Auslender R, Abramovici H (1997) Supplementation iron intravenously in pregnancy. Away to avoid blood transfusions. J Reprod Med 42:99–103
Ayrıntılar
Birincil Dil
İngilizce
Konular
Kadın Hastalıkları ve Doğum
Bölüm
Araştırma Makalesi
Yazarlar
Zeliha Demirel
0000-0002-9300-7329
Türkiye
Erhan Aktürk
0000-0003-1436-6049
Türkiye
Melahat Atasever
0000-0001-8232-4719
Türkiye
Yayımlanma Tarihi
31 Aralık 2019
Gönderilme Tarihi
29 Aralık 2019
Kabul Tarihi
31 Aralık 2019
Yayımlandığı Sayı
Yıl 2019 Cilt: 16 Sayı: 4